Shire plc: История британской биофармацевтической компании

British pharmaceutical company

Shire plc was a UK founded Jersey registered specialty biopharmaceutical company. Originating in the United Kingdom with an operational base in the United States, its brands and products included Vyvanse, Lialda, and Adderall XR. Shire was acquired by Takeda Pharmaceutical Company on 8 January 2019. Shire was a global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. The company's products were available in more than 100 countries across core therapeutic areas including Hematology, Immunology, Neuroscience, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; a growing franchise in Oncology; and an emerging, innovative pipeline in Ophthalmics. The original corporate headquarters was located in Basingstoke, Hampshire, England. Main offices are located in Dublin, Ireland, the United States in Cambridge, Massachusetts, and Chicago, Illinois, and in Zug, Switzerland. In addition, Shire owns manufacturing sites in Lexington, Massachusetts, and Social Circle, Georgia. Shire's headquarters in Lexington, Massachusetts, will be integrated with Takeda's new U. S. headquarters, which is being relocated from Deerfield, Illinois, to the Boston area.

Shire was founded in 1986 in the UK by five entrepreneurs: Harry Stratford, Dennis Stephens, Peter Moriarty, Geoff Hall and Dr Jim Murray. Under the management of Rolf Stahel, Shire was first listed on the London Stock Exchange in 1996. Shire's initial products were calcium supplements (Calcichew D3) for patients seeking to treat or prevent osteoporosis. In 1997 the company acquired Pharmavene for £105 million in order to access Pharmavene's drug delivery methods. Later in the same year Shire acquired Richwood Pharmaceutical Company, forming Shire Richwood Inc.

In 2001 the company acquired Biochem Canada. Shire's next acquisition didn't come until 2005 when it acquired Transkaryotic Therapeutics and two years later – in 2007 – New River Pharmaceuticals Inc, for a then company record of $2.6 billion. With the purchase of New River, Shire gained access and ownership of Vyvanse. A year later the company acquired the German company Jerini, for $521 million. Jerini focused on treating hereditary angioedema. In 2008, in reaction to new taxation measures announced by the UK government in the treatment of royalties on patents, the company moved its tax domicile to Dublin, Ireland.

On 20 June 2014, Shire rejected a takeover attempt by AbbVie. AbbVie offered £46.11 per share (£27.3 billion or $46.5 billion in total). On 8 July, the offer was increased to $51.5 billion. On 18 July, it was announced that AbbVie would acquire Shire for $54.8 billion. On 15 October, news broke suggesting AbbVie was reconsidering their proposed takeover deal due to changes in US "Tax Inversion" law and on 16 October AbbVie's board recommended that shareholders vote against the deal. This news sent Shire's share price down over 27%; however, AbbVie would be subject to a $1.6 billion break up fee, payable to Shire. On 21 October, the merger was called off.

In April 2018, reported that Takeda Pharmaceutical Company had an approach to acquire Shire. Days later Shire announced they had rejected all three Takeda bids. The first bid valued the business at £41 billion (£28 per Shire shares paid in Takeda shares plus £16 per share in cash), the second £43 billion (£28.75 per Shire shares paid in Takeda shares plus £16.75 per share in cash) and the third £44 billion (£28 per Shire shares paid in Takeda shares plus £17.75 per share in cash). Reuters also reported interest from Allergan however they ruled themselves out a day later. A day later Takeda increased their offer with a fourth bid, to £26 per Shire shares paid in Takeda shares plus £21 per share in cash giving a total value of £44.3 billion ($62.1 billion). On 24 April, Takeda submitted an enhanced fifth bid for the company. On 25 April, Shire said that they will recommend the revised £45.8 billion ($64 billion) offer to their shareholders. The enhanced offer included a more generous cash component, with the deal offering £21.76 ($30.33) in cash for each Shire ordinary share. The same day, GlaxoSmithKline ruled out making any form of counter bid. On 8 May 2018, an agreement was finally reached in which Shire was sold to Takeda in a $62 billion deal. Takeda's acquisition of Shire closed on 8 January 2019.

In July 2014, Shire licensed the rights to the investigational Hunter syndrome compound, AGT 182, from ArmaGen for up to $225 million. The Annual Revenue figures in the following Table were drawn from the company's 2015 preliminary results. Ginger Gregory as chief human resources officer, Jeffrey Poulton as CFO, and Philip Vickers as head of R&D. James Bowling vacated his position as interim CFO in the aftermath of the collapse of the AbbVie inversion deal. The chair of Shire's board of directors was Susan Kilsby.

In September 2014, Shire reached a $56.5 million settlement with the U. S. Department of Justice for alleged violations of the False Claims Act. The Justice Department alleged that Shire had improperly marketed and promoted Adderall XR, Daytrana, Vyvane, Pentasa, and Lialda during various periods between 2004 and 2010. The allegations included claims that Shire had made exaggerated and false statements regarding product safety, promoted medications for non FDA approved off label use, and marketed products on unsubstantiated claims of beneficial side effects, including reductions in criminality, traffic accidents, sexually transmitted infections, and divorce rates.

In August 2017, Shire reached a $350 million settlement with the Department of Justice for violations of the same act, regarding the unlawful promotion of Shire's product Dermagraft.